SNDX News and Press, Syndax Pharmaceuticals Inc. From 11/03/25

2025-11-03 16:04:10 ET More on Syndax Pharmaceuticals Syndax Expands Revuforj Approval, Buy Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript Syndax Pharmaceuticals, Inc. (...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at...

– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/...

Hess Midstream LP Class A Representing Limited Partner Interests (HESM) is expected to report $0.73 for Q3 2025 IDEAYA Biosciences Inc. (IDYA) is expected to report $0 for Q3 2025 Unum Group (UNM) is expected to report $2.15 for Q3 2025 CNA Financial Corporation (CNA) is expected to r...

2025-11-02 16:35:00 ET More on Syndax Pharmaceuticals Syndax Expands Revuforj Approval, Buy Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript Syndax Pharmaceuticals, Inc. (...

2025-11-02 09:00:00 ET Late last year, I covered Kura Oncology ( KURA ) as a potential contender in the field of precision medicine, initiating a Strong Buy at $9.12/share following a major drop in the stock. The drop coincided with Kura announcing a collaboration with t...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, ...

2025-10-26 23:44:22 ET Thesis Read the full article on Seeking Alpha For further details see: Syndax Expands Revuforj Approval, Buy

2025-10-24 20:47:37 ET Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT... Read the full article on Seeking Alpha For further details see: Syndax Pharmaceuticals...

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Syndax’s leadership in me...